UTHR News and Press, United Therapeutics Corporation From 11/02/22

United Therapeutics Corporation (UTHR) Q3 2022 Earnings Conference Call November 02, 2022 9:00 AM ET Company Participants Dewey Sedman – Head-Investor Relations Martine Rothblatt – Chairperson and Chief Executive Officer Michael Benkowitz – P...

United Therapeutics ( NASDAQ: UTHR ) stock soared ~12% on Wednesday after Q3 results surpassed analysts estimates. GAAP EPS rose +43.57% Y/Y to $4.91. Total revenues grew +16% Y/Y to $516M. "We are thrilled to report the highest quarterly revenue in our his...

United Therapeutics press release ( NASDAQ: UTHR ): Q3 GAAP EPS of $4.91 beats by $1.10 . Revenue of $516M (+16.0% Y/Y) beats by $22.54M . “We are extremely pleased to have achieved several commercial milestones in the third quarter, highlighted by Tyvas...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third qu...

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the Credit Suisse 31 st Annual Health...

United Therapeutics ( NASDAQ: UTHR ) said a short induction of Remodulin (treprostinil) injection allowed patients to reach double the typical doses of its other drug Orenitram (treprostinil) extended-release tablets than patients who did not have a Remodulin induction. ...

A short induction of Remodulin ® (treprostinil) injection allowed study subjects to reach double the typical doses of Orenitram ® (treprostinil) extended-release tablets than patients who did not have a Remodulin induction United Therapeutics Corporation (N...

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022. United Therapeutics will host a public webcast Wednesday, November 2, 2022, at 9:00 a.m. Eastern Time. ...

Data from the INCREASE open label extension study of Tyvaso ® detail its long-term safety and tolerability in pulmonary hypertension associated with interstitial lung disease Data from the FREEDOM-EV open label extension study of Orenitram ® details a...

Second registration study of Tyvaso ® (treprostinil) Inhalation Solution for patients with IPF United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the phase 3 TETON 2 study...